# SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers

Source: https://onco.cc/trials/nct07080619/  
OnCo record `nct07080619` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of SC-101 run by Tianjin ConjuStar Biologics Co., Ltd., now recruiting.

## Summary

SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers is a phase 2 interventional study registered as NCT07080619 by Tianjin ConjuStar Biologics Co., Ltd., with 120 participants planned, started 2025-08-26. Conditions recorded: TNBC - Triple-Negative Breast Cancer and HR+ Breast Cancer. Interventions recorded: SC-101.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07080619
- Phase: 2
- Setting: A Phase IIa Clinical Study to Assess the Efficacy and Safety of SC-101 in Patients With Advanced Malignant Tumors Positive for NECTIN4 Gene Amplification
- Sponsor: Tianjin ConjuStar Biologics Co., Ltd.
- Enrolled: 120

## Sources

- ClinicalTrials.gov NCT07080619: https://clinicaltrials.gov/study/NCT07080619

## Connected records

- cancers: [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [SC-101](https://onco.cc/drugs/sc-101/)
- companies: [ConjuStar Biologics](https://onco.cc/companies/conjustar-biologics/)

---
JSON: https://onco.cc/api/v1/entities/nct07080619.json